Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems

被引:5
作者
Ghorai, Suvankar [1 ,2 ]
Shand, Harshita [2 ]
Patra, Soumendu [2 ]
Panda, Kingshuk [1 ]
Santiago, Maria J. [1 ,3 ]
Rahman, Md. Sohanur [1 ]
Chinnapaiyan, Srinivasan [1 ]
Unwalla, Hoshang J. [1 ]
机构
[1] Florida Int Univ, Herbert Wertheim Coll Med, Dept Cellular & Mol Med, 11200 SW 8th St, Miami, FL 33199 USA
[2] Raiganj Univ, Dept Microbiol, Raiganj 733134, India
[3] Florida Int Univ, Dept Chem & Biochem, 11200 SW 8th St, Miami, FL 33199 USA
关键词
HIV/AIDS; nanomedicine; nano vaccine; RNA virus; nano-herbal; INFLUENZA-VIRUS; IN-VITRO; SILVER NANOPARTICLES; NEUTRALIZING ANTIBODY; ANTIRETROVIRAL DRUG; NASAL IMMUNIZATION; HIV-1; INFECTION; DELIVERY-SYSTEM; HTLV-I; VACCINE;
D O I
10.3390/pharmaceutics16030407
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The continuous evolution of new viruses poses a danger to world health. Rampant outbreaks may advance to pandemic level, often straining financial and medical resources to breaking point. While vaccination remains the gold standard to prevent viral illnesses, these are mostly prophylactic and offer minimal assistance to those who have already developed viral illnesses. Moreover, the timeline to vaccine development and testing can be extensive, leading to a lapse in controlling the spread of viral infection during pandemics. Antiviral therapeutics can provide a temporary fix to tide over the time lag when vaccines are not available during the commencement of a disease outburst. At times, these medications can have negative side effects that outweigh the benefits, and they are not always effective against newly emerging virus strains. Several limitations with conventional antiviral therapies may be addressed by nanotechnology. By using nano delivery vehicles, for instance, the pharmacokinetic profile of antiviral medications can be significantly improved while decreasing systemic toxicity. The virucidal or virus-neutralizing qualities of other special nanomaterials can be exploited. This review focuses on the recent advancements in nanomedicine against RNA viruses, including nano-vaccines and nano-herbal therapeutics.
引用
收藏
页数:21
相关论文
共 138 条
[41]   Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2 [J].
Granados-Riveron, Javier T. ;
Aquino-Jarquin, Guillermo .
BIOMEDICINE & PHARMACOTHERAPY, 2021, 142
[42]   Nanomedicines for dysfunctional macrophage-associated diseases [J].
He, Hongliang ;
Ghosh, Shobha ;
Yang, Hu .
JOURNAL OF CONTROLLED RELEASE, 2017, 247 :106-126
[43]  
Hekmat S., 2017, Vaccine research, V4, P13, DOI [10.29252/vacres.3.8.9.48, DOI 10.29252/VACRES.3.8.9.48]
[44]   Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: Implications for structural analyses of gp120-DC-SIGN binding [J].
Hong, PWP ;
Flummerfelt, KB ;
de Parseval, A ;
Gurney, K ;
Elder, JH ;
Lee, B .
JOURNAL OF VIROLOGY, 2002, 76 (24) :12855-12865
[45]   Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection [J].
Hu, Che-Ming Jack ;
Chen, You-Ting ;
Fang, Zih-Syun ;
Chang, Wei-Shan ;
Chen, Hui-Wen .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2018, 13 :8579-8593
[46]   Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches [J].
Huang, Jing ;
Li, Yuancheng ;
Orza, Anamaria ;
Lu, Qiong ;
Guo, Peng ;
Wang, Liya ;
Yang, Lily ;
Mao, Hui .
ADVANCED FUNCTIONAL MATERIALS, 2016, 26 (22) :3818-3836
[47]   Antiviral drug resistance as an adaptive process [J].
Irwin, Kristen K. ;
Renzette, Nicholas ;
Kowalik, Timothy F. ;
Jensen, Jeffrey D. .
VIRUS EVOLUTION, 2016, 2 (01)
[48]   Development of Biodegradable Nanoparticles for Liver-Specific Ribavirin Delivery [J].
Ishihara, Tsutomu ;
Kaneko, Kohei ;
Ishihara, Tomoaki ;
Mizushima, Tohru .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (12) :4005-4011
[49]   Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA [J].
Jamali, Abbas ;
Mottaghitalab, Fatemeh ;
Abdoli, Asghar ;
Dinarvand, Meshkat ;
Esmailie, Aida ;
Kheiri, Masoumeh Tavassoti ;
Atyabi, Fatemeh .
DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2018, 8 (01) :12-20
[50]   A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine [J].
Jangra, Sonia ;
Landers, Jeffrey J. ;
Rathnasinghe, Raveen ;
O'Konek, Jessica J. ;
Janczak, Katarzyna W. ;
Cascalho, Marilia ;
Kennedy, Andrew A. ;
Tai, Andrew W. ;
Baker, James R., Jr. ;
Schotsaert, Michael ;
Wong, Pamela T. .
FRONTIERS IN IMMUNOLOGY, 2021, 12